This study will collect biological samples for use in research experiments aimed at better understanding the clinical features of certain diseases. The specimens may be used to evaluate the effectiveness of known therapies, refine treatment approaches, identify potential new therapies, and explore opportunities for disease prevention. The following individuals 2 years of age or older may be eligible for this study: - Patients with a cancerous solid tumor or a cancerous or non-cancerous blood disorder who are being screened for or who are enrolled in a treatment study at the NIH Clinical Center - HLA-compatible donor family members (18 years of age or older) of the above patients who are being evaluated for or are enrolled in an NIH study as a stem cell transplant donor - Patients with a cancerous solid tumor or a cancerous or non-cancerous blood disorder or a bone marrow failure condition who cannot participate in an NIH treatment protocol or travel to the NIH Clinical Center and who are referred for participation through their home health care provider. Research samples will be collected from participants when blood is drawn or bone marrow, urine, or stool is collected, or tumor or other tissue is biopsied as part of their general medical care. Investigators may periodically request an additional sample of blood, stool, or urine. Participants who are 18 years of age or older may donate a large number of white blood cells through a procedure called leukapheresis. This procedure is not part of general medical care and would be done for research purposes only. For apheresis, a catheter (plastic tube) is placed in a vein in the subject's arm. Blood flows from the vein into a cell separator machine, where the white cells are separated from the red cells, platelets, and plasma by a spinning process. The white cells are removed and collected, and the rest of the blood is returned to the subject through a second tube placed in the other arm.

Population

The subject carries the diagnosis of malignant solid tumor or a malignant or non-malignant hematologic disorder; carries the diagnosis of malignant solid tumor or a malignant or non-malignant hematologic disorder; is a HLA-compatible family member of a patient (bearing a diagnosis of malignant solid tumor or a malignant or non-malignant hematologic disorder) being evaluated for or already enrolled on a clinical protocol at the NIH Clinical Center and is identified as a potentially suitable donor of allogeneic hematopoietic stem cells for transplantation; carries the diagnosis of malignant solid tumor or a malignant or non-malignant hematologic disorder or a bone marrow failure condition and is not available to participate in an NIH Clinical Center treatment protocol, or travel to the NIH Clinical Center, but is referred for participation through their home health care provider.

Brief Title

Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members

Official Title

Collection of Blood, Bone Marrow, Urine, and/or Tissue Samples From Patients With Solid Tumors, Hematological Malignancies or Non-Malignant Hematologic Disorders or HLA Compatible Family Members

Brief Summary

This study will collect biological samples for use in research experiments aimed at better <br /> understanding the clinical features of certain diseases. The specimens may be used to <br /> evaluate the effectiveness of known therapies, refine treatment approaches, identify <br /> potential new therapies, and explore opportunities for disease prevention. <br /> <br /> The following individuals 2 years of age or older may be eligible for this study: <br /> <br /> - Patients with a cancerous solid tumor or a cancerous or non-cancerous blood disorder who <br /> are being screened for or who are enrolled in a treatment study at the NIH Clinical <br /> Center <br /> <br /> - HLA-compatible donor family members (18 years of age or older) of the above patients who <br /> are being evaluated for or are enrolled in an NIH study as a stem cell transplant donor <br /> <br /> - Patients with a cancerous solid tumor or a cancerous or non-cancerous blood disorder or <br /> a bone marrow failure condition who cannot participate in an NIH treatment protocol or <br /> travel to the NIH Clinical Center and who are referred for participation through their <br /> home health care provider. <br /> <br /> Research samples will be collected from participants when blood is drawn or bone marrow, <br /> urine, or stool is collected, or tumor or other tissue is biopsied as part of their general <br /> medical care. Investigators may periodically request an additional sample of blood, stool, or <br /> urine. Participants who are 18 years of age or older may donate a large number of white blood <br /> cells through a procedure called leukapheresis. This procedure is not part of general medical <br /> care and would be done for research purposes only. For apheresis, a catheter (plastic tube) <br /> is placed in a vein in the subject's arm. Blood flows from the vein into a cell separator <br /> machine, where the white cells are separated from the red cells, platelets, and plasma by a <br /> spinning process. The white cells are removed and collected, and the rest of the blood is <br /> returned to the subject through a second tube placed in the other arm.

Detailed Description

The purpose of this protocol is to collect blood, bone marrow, urine, stool, oral samples,
nasopharyngeal samples and/or both malignant and non-malignant tissue from patients who are
either being evaluated for enrollment, are consented to NIH Clinical Center treatment
protocols, or are receiving therapy for their disease through home health care providers.
Since a substantial proportion of the clinical and translational research in the NHLBI
involves patients undergoing allogeneic stem cell transplantation, this protocol will also be
open to people identified as suitable HLA compatible donors for patients undergoing
evaluation for or already enrolled in an allogeneic stem cell transplant protocol or
receiving a stem cell transplant through their home health care providers. These HLA
compatible donors will serve as a source of peripheral blood mononuclear cells (peripheral
blood draws or leukapheresis) for use in evaluating allogeneic graft versus host and
graft-versus-tumor effects.

The primary objective is to provide a mechanism for collection, tracking, storing,
dispensing, analyzing, and disposing of these laboratory research samples from patients and
HLA matched donors.

There is no primary endpoint.

Outcome Measures

Outcome measures are the tests that investigators perform to prove whether or not a treatment being tested in a clinical trial is having any effect.